Growing global tech businesses
out of Bristol
Helping you make your impact in the world
Our support is designed for you. If you join us, you’ll enjoy tailored support crafted around your ambitions and introductions to an amazing network of companies and advisers.
Your success is our success
We’ve helped over 450 companies, in 20+ sectors, raise over £710 million in investment.
Fast track your tech business
Hear from our companies on how SETsquared Bristol has helped them grow their businesses.
![Discover_SETSquared_Logo Discover SETSquared Logo](https://setsquared-bristol.co.uk/wp-content/uploads/2021/11/Discover_SETSquared_Logo.png)
Calling all tech entrepreneurs
Take your business to the next stage. Come to our next Discover SETsquared open event on 22 October at 11 am.
Featured news and insights
![DRIFT Energy's fleet of net positive ships - 2024 PR DRIFT Energy’s fleet of net positive ships (MVY – Most Valuable Yachts) - credit DRIFT Energy](https://setsquared-bristol.co.uk/wp-content/uploads/bb-plugin/cache/DRIFT-Energys-fleet-of-net-positive-ships-2024-PR-1024x1024-landscape-77f3b8950aec4af800a7fbc90b162da3-.jpg)
DRIFT Energy plans first green hydrogen-producing vessel build following seed investment
DRIFT Energy has announced the close of its seed funding round led by Octopus Ventures, and with support from Blue Action Accelerator, the company has secured a total of £4.65...
![FluoretiQ_patent image 2024 FluoretiQ founders smiling with technology on PC](https://setsquared-bristol.co.uk/wp-content/uploads/bb-plugin/cache/FluoretiQ_patent-image-2024-landscape-59b76f0b46c19458f9821af8373161e0-.png)
FluoretiQ patent granted to enable fast and accurate antibiotic testing
Bristol-based biotech company, FluoretiQ, who is developing fast and accurate point-of-care testing for Urinary Tract Infections (UTIs) and Sexually Transmitted Diseases (STDs), has taken a significant step forward after having...
![CARB-X-blog-1 GenomeKey blood sample in lab](https://setsquared-bristol.co.uk/wp-content/uploads/bb-plugin/cache/CARB-X-blog-1-landscape-768936dc918f03a52fb3787704d51107-.jpg)
GenomeKey awarded $11.4M to transform sepsis diagnosis and treatment
GenomeKey has been awarded a major grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to build a functioning, automated prototype of their desktop diagnostic device. The Bristol-based company joined our...